Seaport Therapeutics Aims for $912 Million Valuation in US IPO

Drug developer Seaport Therapeutics is targeting a valuation of $912 million in its upcoming initial public offering in the United States.

27 Apr, 10:53 — 27 Apr, 12:31

Post Share

Why this matters

An initial public offering allows a private company to offer shares to the public, raising capital for growth and development. For Seaport Therapeutics, a successful IPO could provide significant funding for drug development and research, potentially bringing new treatments to market.

Key entitiesSeaport Therapeutics

The Story

What 2 sources agree on, dispute, and miss

What sources agree on

Seaport Therapeutics is a drug developer
Seaport Therapeutics is pursuing a U.S. IPO

Key claims2 unverified

Seaport Therapeutics is seeking up to $212 million in its US IPO

unverified·seeking-alpha

Seaport Therapeutics is targeting a $912 million valuation in its US IPO

unverified·Reuters

Coverage gaps

The target valuation of $912 million for Seaport Therapeutics' IPO

ReportedReuters

Missingseeking-alpha

The target amount to be raised, up to $212 million, in Seaport Therapeutics' IPO

Reportedseeking-alpha

MissingReuters

The Story

Analyzing sources…

Source Diversity

Moderate (32/100)

2 sources— more sources would strengthen this score15/33

Spectrum spread— 2/5 buckets covered8/33

Far L

Left

Center1

Center (1)

Reuters

Right1

Right (1)

seeking-alpha

Far R

Geographic diversity— 2 regions9/34

US1Intl1

ℹOnly 2 sources cover this story

Political spectrum

LeftCenterRight

reuters

seeking-alpha

Outlet rating This story

SourceOutletiGeneral editorial lean of the outletStoryiHow they covered this specific storyToneFactuality

ReuterscentercenterneutralVery Highneutral, factual reporting of corporate news

seeking-alphacenterrightneutralMixedfocuses on financial details, market-oriented

Coverage leans: balanced

The coverage is balanced, with both outlets providing factual reporting on a corporate financial event without apparent political framing.

Sources

Showing 2 of 2 sources

ReutersVery High104d ago

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO - Reuters

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO Reuters

Read full article →

seeking-alphaMixed104d ago

Drug developer Seaport Therapeutics seeks up to $212M in US IPO

Read full article →

Coverage Timeline

First report: Reuters · 27 Apr, 10:53|Full coverage: 2 · 2h|Window: 2h

Left-leaningCenterRight-leaning

Reuters27 Apr, 10:53First to report

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO - Reuters

2h later

seeking-alpha27 Apr, 12:31Latest update

PERSPECTA

PERSPECTA

Seaport Therapeutics Aims for $912 Million Valuation in US IPO

Why this matters

The Story

What sources agree on

Key claims2 unverified

Coverage gaps

The Story

Source Diversity

Source Diversity

Political spectrum

Sources

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO - Reuters

Drug developer Seaport Therapeutics seeks up to $212M in US IPO

Coverage Timeline

Drug developer Seaport Therapeutics targets $912 million valuation in US IPO - Reuters

Drug developer Seaport Therapeutics seeks up to $212M in US IPO

Related Stories

Retirees Can Withdraw Up To $47,500 From IRAs Tax-Free

Powerball Jackpot Winning Numbers Announced

Choosing the Right Index Fund: Hallgeir Kvadsheim's Advice

Best Time for Autumn Holidays: Two Months Financially Favorable

PERSPECTA

Political spectrum

Why this matters

The Story

What sources agree on

Key claims2 unverified

Coverage gaps

Coverage matrix